| NCT ID | NCT06706570 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | Breast Cancer Metastatic |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-11-06 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-11-06 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluation of PIK3CA mutational status: a route towards a tailored diagnostic approach.
Eligibility Criteria
Inclusion Criteria: * Participant has a histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ breast cancer by local laboratory. * Participant has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (Fluorescent in situ hybridization (FISH), Chromogenic in situ hybridization (CISH), or Silver-enhanced in situ hybridization (SISH)) test is required by local laboratory testing. * Participants should be at advanced or metastatic setting prior to treatment. * Written informed consent must be signed and dated by the patient and the investigator prior to inclusion. * Patients must be accessible for follow-up. Exclusion Criteria: • patients already treated with different treatments like chemotherapy, hormone therapy etc
Contact & Investigator
Nicola Fusco, MD
PRINCIPAL INVESTIGATOR
Istituto Europeo di Oncologia
Frequently Asked Questions
Who can join the NCT06706570 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer Metastatic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06706570 currently recruiting?
Yes, NCT06706570 is actively recruiting participants. Contact the research team at nicola.fusco@ieo.it for enrollment information.
Where is the NCT06706570 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06706570 clinical trial?
NCT06706570 is sponsored by European Institute of Oncology. The principal investigator is Nicola Fusco, MD at Istituto Europeo di Oncologia. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.